Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANXFree Report) by 85.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,770 shares of the company’s stock after selling 10,097 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Janux Therapeutics were worth $48,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its position in Janux Therapeutics by 6.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company’s stock valued at $320,000 after purchasing an additional 727 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Janux Therapeutics by 13.3% in the first quarter. Bank of New York Mellon Corp now owns 89,370 shares of the company’s stock worth $2,413,000 after acquiring an additional 10,511 shares during the last quarter. KBC Group NV purchased a new position in Janux Therapeutics in the first quarter worth approximately $66,000. Allspring Global Investments Holdings LLC grew its holdings in Janux Therapeutics by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company’s stock worth $244,000 after acquiring an additional 3,168 shares in the last quarter. Finally, FNY Investment Advisers LLC increased its position in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after purchasing an additional 2,425 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Trading Down 4.9%

Shares of JANX opened at $26.40 on Friday. The company’s 50 day simple moving average is $24.62 and its 200-day simple moving average is $31.44. The firm has a market cap of $1.56 billion, a PE ratio of -19.41 and a beta of 2.86. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They set an “outperform” rating and a $65.00 price objective for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics currently has an average rating of “Buy” and an average price target of $91.89.

Check Out Our Latest Stock Analysis on JANX

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the business’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider owned 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 8.10% of the company’s stock.

About Janux Therapeutics

(Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Further Reading

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANXFree Report).

Institutional Ownership by Quarter for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.